Naptumomab 

Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma^[1][2].

Fab-G1-kappa

Human

TPBG

7162  [NCBI]

Q13641

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

1412892-09-1

Liquid

Colorless to light yellow

[Naptumomab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized Naptumomab can bind Human 5T4/TPBG Protein (His Tag). The EC₅₀ for this effect is 0.704 ng/mL.
• 
  Flow Cytometry analysis of MCF-7 cells with Naptumomab (HY-P99035, red) . Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Matthew K Robinson, et al. Naptumomab estafenatox: a new immunoconjugate. Expert Opin Biol Ther. 2010 Feb;10(2):273-9.  [Content Brief]

  [2]. Tim Eisen, et al. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.  [Content Brief]